NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | 0.02 | 0.01 |
| FCF Yield | -83,478.18% | -115.09% | -55.78% | -91.45% |
| EV / EBITDA | 4.60 | 1.94 | 0.53 | 1.58 |
| Quality | ||||
| ROIC | -19.44% | -22.06% | -20.40% | -22.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.10 | 1.06 | 0.84 | 1.30 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 45.04% | -5.27% | 39.67% | 13.94% |
| Safety | ||||
| Net Debt / EBITDA | 4.61 | 2.95 | 2.17 | 3.42 |
| Interest Coverage | -23,057.38 | -5,052.05 | -1,768.90 | -2,462.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.75 | 0.00 |
| Cash Conversion Cycle | -93.02 | -95.38 | -144.03 | 0.00 |